Loading page...
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 9 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Based on projects the EU funded on the same subject in this programme.
CO-CAPTAINCANCER PREVENTION AMONG INDIVIDUALS WITH MENTAL ILL-HEALTH: CO-ADAPTING AND IMPLEMENTING PATIENT NAVIGATION FOR PRIMARY CANCER PREVENTION
HORIZON-MISS-2022-CANCER-01-01 · 2023 · Official record ↗
ENACT-65ENabling ACTion on Integrated Nutritional and Exercise Care in Cancer – for Patients 65 and Beyond
HORIZON-MISS-2025-02-CANCER-05 · 2026 · Official record ↗
NutriCa65PERSONALISED NUTRITIONAL CARE FOR OLDER PATIENTS WITH LEUKAEMIA OR PANCREATIC CANCER – A PRAGMATIC IMPLEMENTATION TRIAL TO IMPROVE QUALITY OF LIFE
HORIZON-MISS-2025-02-CANCER-05 · 2026 · Official record ↗
PALACROSPrioritising multimodal surgical care for patients with locally advanced pancreatic cancer across Europe
HORIZON-MISS-2025-02-CANCER-03 · 2026 · Official record ↗
PanCare4AYAPatient-centred, evidence-based late effect screening and follow-up care of survivors of adolescent and young adult cancer
HORIZON-MISS-2024-CANCER-01-05 · 2025 · Official record ↗
CCI4EUCOMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE
HORIZON-MISS-2022-CANCER-01-02 · 2023 · Official record ↗
EU-CIPEUropean Cancer Information Portal
HORIZON-MISS-2024-CANCER-01-06 · 2025 · Official record ↗
PREMIO COLLABPersonalised response monitoring in oncology: co-creating clinical trials in advanced breast cancer
HORIZON-MISS-2023-CANCER-01-03 · 2024 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to the following expected outcomes:
This topic contributes to the EU Cancer Mission’s objective to improve quality of life of cancer patients. The focus is on cancer patients aged 65 years and above.
Currently, older cancer patients represent the largest proportion of cancer patients especially in Europe, with more than two thirds of new cancer cases being diagnosed in patients above the age of 65. Yet, there is still relatively little knowledge about their functional health and care needs during and after treatment.
Managing cancer in older patients is complex, due to the high heterogeneity in terms of their intrinsic health capacities, including mental health and cognitive capacities, comorbidities, frailty etc. as well as with regard to their performance activities including social interactions, work, mobility etc. Consequently, overall health care needs of older patients with cancer vary significantly.
Older cancer patients are consistently underrepresented in clinical research, with representation declining progressively with increasing age. This leads to a lack of knowledge regarding treatments, specific needs, and clinical endpoints. Older patients are also particularly vulnerable to treatment toxicities loss of muscle mass, and may experience a large variety of confounding comorbidities and symptoms, which strongly impact their quality of life during and after treatment.
As such, quality of life expectations should be systematically factored in the decision process to define the optimal approach to cancer management.
The overall goal of this topic is to advance the understanding of older cancer patients' care needs, and develop innovative, age-sensitive care approaches and tools to boost overall quality of life. In particular:
The topic is designed to fill a gap in terms of evidence, knowledge, expertise, tools, data and resources in the management of older cancer patients. This should be achieved through multinational, cross-sectoral and multidisciplinary cooperation.
For that purpose, projects should include an appropriate mix of stakeholders from various disciplines and sectors, including but not limited to physicians, psychologists, nurses, academia, patients and their caregivers, patient representatives, behavioural scientists, SMEs, insurance companies, charities and foundations, research organisations, civil society, regional and national health authorities
In particular, direct involvement of cancer patients and survivors, survivor representative organisations, and caregivers is required, along with effective contribution of SSH disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant results, enhancing the impact of the related research activities.
Successful proposals will be asked to join the 'Quality of life” cluster for the EU Cancer Mission[1] and should include a budget for networking, attendance at meetings, and joint activities[2]. The Commission will facilitate coordination of these activities.
Applicants should provide details of the clinical studies in the dedicated annex using the template provided in the submission system.
[1] In order to address the objectives of the EU Cancer Mission, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of EU Cancer Mission R&I and policy actions.
[2] Examples of these activities are research or research capacity, organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Proposals are not required to include details of these activities, as they will be defined during the grant agreement preparation phase and during the life of the project
1. Admissibility conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
2. Eligible countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.
described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
described in Annex G of the Work Programme General Annexes.
described in the specific topic of the Work Programme.
Application and evaluation forms and model grant agreement (MGA):
Application form templates
Please use the application form that you will find in the Submission System. You can find examples of standard application forms in the Reference Documents page.
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA)
Guidance
HE Programme Guide
Model Grant Agreements (MGA)
HE MGA
Call-specific instructions
Information on clinical studies (HE)
Additional documents:
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 12. Missions
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Framework Programme and Rules for Participation Regulation 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Applicants asked the EU 1 questions about this call and the EU published the answers. They clarify the call documents but do not replace them.
Yes, cachexia is within the scope of this topic given its impact on the quality of life of cancer patients. Both pharmacological and non-pharmacological interventions are within the scope of this topic.
Read it on the EU portal ↗Answered 11 Jul 2026
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.